Research programme: metabolic disorders therapy - ObeTherapy Biotechnology/Zambon
Alternative Names: Lipid absorption inhibitors - ZambonLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator ObeTherapy Biotechnology; Zambon Group SpA
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Metabolic syndrome
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-syndrome in France
- 08 Nov 2004 Preclinical trials in Metabolic syndrome in France (unspecified route)